# Safety and Efficacy of AMG 827 in Subjects With RA

> **NCT01059448** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 211 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** AMG 827

## Key facts

- **NCT ID:** NCT01059448
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06-03
- **Primary completion:** 2011-04-05
- **Final completion:** 2011-04-05
- **Target enrollment:** 211 (ACTUAL)
- **Why stopped:** Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059448, "Safety and Efficacy of AMG 827 in Subjects With RA". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01059448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*